Search research articles
Contact Us
Filters
Showing results (51-60 of 57) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 57 results.
The New England Journal of Medicine
|
December 8, 2021
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Leonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
The New England Journal of Medicine
|
May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Mario Castro, Jonathan Corren, Ian D Pavord, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis
Jorge F Maspero, Constance H Katelaris, William W Busse, et al.
The Lancet. Respiratory Medicine
|
October 1, 2021
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
Michael E Wechsler, Linda B Ford, Jorge F Maspero, et al.
Lancet (London, England)
|
September 18, 2022
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
Amy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
The New England Journal of Medicine
|
December 22, 2022
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Evan S Dellon, Marc E Rothenberg, Margaret H Collins, et al.
Lancet (London, England)
|
September 24, 2019
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert, Joseph K Han, Martin Desrosiers, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 57) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 57 results.
The New England Journal of Medicine
|
December 8, 2021
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Leonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
The New England Journal of Medicine
|
May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Mario Castro, Jonathan Corren, Ian D Pavord, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis
Jorge F Maspero, Constance H Katelaris, William W Busse, et al.
The Lancet. Respiratory Medicine
|
October 1, 2021
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
Michael E Wechsler, Linda B Ford, Jorge F Maspero, et al.
Lancet (London, England)
|
September 18, 2022
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
Amy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
The New England Journal of Medicine
|
December 22, 2022
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Evan S Dellon, Marc E Rothenberg, Margaret H Collins, et al.
Lancet (London, England)
|
September 24, 2019
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert, Joseph K Han, Martin Desrosiers, et al.
Page
of 6